Delisting risk
Estrella Immunopharma (ESLA)
Develops ARTEMIS T-cell therapies for B-cell malignancies.
$0.6900
At close−0.00 (−0.22%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 1 | 0 | 4 | 3 | 1 | 2 | 6 | 5 | 1 | 2 | 2 | |
| Research & development | 0 | 0 | 0 | 4 | 3 | 0 | 1 | 5 | 4 | 0 | 1 | 1 |
| 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| General & administrative | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Operating income | −2 | −1 | 0 | −4 | −3 | −1 | −2 | −6 | −5 | −1 | −2 | −2 |
| Other income (expense), net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −2 | −1 | 0 | −4 | −3 | −1 | −2 | −6 | −5 | −1 | −2 | −2 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −2 | −1 | 0 | −4 | −3 | −1 | −2 | −6 | −5 | −1 | −2 | −2 |
| Net income | −2 | −1 | 0 | −4 | −3 | −1 | −2 | −6 | −5 | −1 | −2 | −2 |
| EPS, basic | −$1.78 | −$0.03 | −$0.01 | −$0.11 | −$0.09 | −$0.03 | −$0.06 | −$0.15 | −$0.13 | −$0.02 | −$0.05 | −$0.05 |
| EPS, diluted | −$1.78 | −$0.03 | −$0.01 | −$0.11 | −$0.09 | −$0.03 | −$0.06 | −$0.15 | −$0.13 | −$0.02 | −$0.05 | −$0.05 |
| Weighted average shares, basic | 1 | 35 | 36 | 37 | 36 | 37 | 36 | 36 | 37 | 38 | 42 | 43 |
| Weighted average shares, diluted | 1 | 35 | 36 | 37 | 36 | 37 | 36 | 36 | 37 | 38 | 42 | 43 |
| EBITDA | −2 | −1 | 0 | −4 | −3 | −1 | −2 | −6 | −5 | −1 | −2 | −2 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −2 | −1 | 0 | −4 | −3 | −1 | −2 | −6 | −5 | −1 | −2 | −2 |